Logo image of INTS

INTENSITY THERAPEUTICS INC (INTS) Stock Overview

NASDAQ:INTS - US45828J1034 - Common Stock

0.3119 USD
+0.01 (+2.56%)
Last: 8/25/2025, 8:00:02 PM
0.3095 USD
0 (-0.77%)
Pre-Market: 8/26/2025, 4:30:25 AM

INTS Key Statistics, Chart & Performance

Key Statistics
52 Week High4.35
52 Week Low0.19
Market Cap14.68M
Shares47.06M
Float40.82M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.82
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-30 2023-06-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


INTS short term performance overview.The bars show the price performance of INTS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60 -80

INTS long term performance overview.The bars show the price performance of INTS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of INTS is 0.3119 USD. In the past month the price decreased by -7.72%. In the past year, price decreased by -92.83%.

INTENSITY THERAPEUTICS INC / INTS Daily stock chart

INTS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.6 366.65B
AMGN AMGEN INC 13.23 155.30B
GILD GILEAD SCIENCES INC 14.75 141.64B
VRTX VERTEX PHARMACEUTICALS INC 22.96 99.72B
REGN REGENERON PHARMACEUTICALS 12.54 60.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.15B
ARGX ARGENX SE - ADR 73.07 41.45B
ONC BEONE MEDICINES LTD-ADR 6.23 36.69B
INSM INSMED INC N/A 27.12B
BNTX BIONTECH SE-ADR N/A 25.26B
NTRA NATERA INC N/A 22.30B
BIIB BIOGEN INC 8.52 19.99B

About INTS

Company Profile

INTS logo image Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. The firm is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.

Company Info

INTENSITY THERAPEUTICS INC

1 Enterprise Drive, Suite 430

Shelton CONNECTICUT US

Employees: 6

INTS Company Website

INTS Investor Relations

Phone: 12032217381

INTENSITY THERAPEUTICS INC / INTS FAQ

What is the stock price of INTENSITY THERAPEUTICS INC today?

The current stock price of INTS is 0.3119 USD. The price increased by 2.56% in the last trading session.


What is the ticker symbol for INTENSITY THERAPEUTICS INC stock?

The exchange symbol of INTENSITY THERAPEUTICS INC is INTS and it is listed on the Nasdaq exchange.


On which exchange is INTS stock listed?

INTS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INTENSITY THERAPEUTICS INC stock?

11 analysts have analysed INTS and the average price target is 2.98 USD. This implies a price increase of 853.84% is expected in the next year compared to the current price of 0.3119. Check the INTENSITY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INTENSITY THERAPEUTICS INC worth?

INTENSITY THERAPEUTICS INC (INTS) has a market capitalization of 14.68M USD. This makes INTS a Nano Cap stock.


How many employees does INTENSITY THERAPEUTICS INC have?

INTENSITY THERAPEUTICS INC (INTS) currently has 6 employees.


What are the support and resistance levels for INTENSITY THERAPEUTICS INC (INTS) stock?

INTENSITY THERAPEUTICS INC (INTS) has a support level at 0.3 and a resistance level at 0.34. Check the full technical report for a detailed analysis of INTS support and resistance levels.


Should I buy INTENSITY THERAPEUTICS INC (INTS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INTENSITY THERAPEUTICS INC (INTS) stock pay dividends?

INTS does not pay a dividend.


What is the Price/Earnings (PE) ratio of INTENSITY THERAPEUTICS INC (INTS)?

INTENSITY THERAPEUTICS INC (INTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.82).


What is the Short Interest ratio of INTENSITY THERAPEUTICS INC (INTS) stock?

The outstanding short interest for INTENSITY THERAPEUTICS INC (INTS) is 4.76% of its float. Check the ownership tab for more information on the INTS short interest.


INTS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

INTS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to INTS. The financial health of INTS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

INTS Financial Highlights

Over the last trailing twelve months INTS reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 17.17% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -283.1%
ROE -575.92%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%63.89%
Sales Q2Q%N/A
EPS 1Y (TTM)17.17%
Revenue 1Y (TTM)N/A

INTS Forecast & Estimates

11 analysts have analysed INTS and the average price target is 2.98 USD. This implies a price increase of 853.84% is expected in the next year compared to the current price of 0.3119.


Analysts
Analysts80
Price Target2.98 (855.43%)
EPS Next Y56.85%
Revenue Next YearN/A

INTS Ownership

Ownership
Inst Owners10.08%
Ins Owners21.24%
Short Float %4.76%
Short Ratio0.21